GoAI
Get started
Lite Strategy, Inc. logo

Lite Strategy, Inc.

LITS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.9897

+$0.0463 · +4.91%

Aug 21, 4:00 PM ET

LITS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

27

Weakening

Sentiment

59

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Justin J. File
Listed since
Dec 18, 2003
Employees
4

Market position

Day range

Current $0.9897

52-week range

Current $0.9897

Open
$1.01
Previous close
$0.9434
Volume
360.82K
1.15× average
Average volume
312.76K
Average daily volume
Market cap
33.67M USD
Beta
0.04
Market reference 1
50-day average
$0.9324
+6.15% above average
200-day average
$1.2148
-18.53% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
12.17M USD
P/E (TTM)
-0.11×
P/B (TTM)
0.12×
P/S (TTM)
0×
EV / EBITDA
-0.71×
Earnings yield
-52.83%
Free cash flow yield
-69.06%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-94.18%
Return on assets
-87.20%
Return on invested capital
-103.09%

Financial health

Debt / equity
0×
Current ratio
13.5×
Altman Z-score
9.54
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends129%14%-100%-214%Gross margin, FY2021: 95.95%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Operating margin, FY2021: -173.65%Operating margin, FY2022: -185.48%Operating margin, FY2023: -75.31%Operating margin, FY2024: 22.27%Net margin, FY2021: -118.73%Net margin, FY2022: -133.80%Net margin, FY2023: -65.22%Net margin, FY2024: 27.23%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 95.95%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Operating margin FY2021 -173.65%. Operating margin FY2022 -185.48%. Operating margin FY2023 -75.31%. Operating margin FY2024 22.27%. Net margin FY2021 -118.73%. Net margin FY2022 -133.80%. Net margin FY2023 -65.22%. Net margin FY2024 27.23%.

Income trends

Revenue

65.3M USD+33.76%

Operating income

−17.46M USD−32M USD

Net income

−15.95M USD−33.72M USD
Income trends across reported periods79.38M USD23.06M USD−33.25M USD−89.56M USDRevenue, FY2021: 34.8M USDRevenue, FY2022: 40.7M USDRevenue, FY2023: 48.82M USDRevenue, FY2024: 65.3M USDOperating income, FY2021: −60.42M USDOperating income, FY2022: −75.48M USDOperating income, FY2023: −36.76M USDOperating income, FY2024: 14.54M USDOperating income, FY2025: −17.46M USDNet income, FY2021: −41.31M USDNet income, FY2022: −54.45M USDNet income, FY2023: −31.84M USDNet income, FY2024: 17.78M USDNet income, FY2025: −15.95M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 34.8M USD. Revenue FY2022 40.7M USD. Revenue FY2023 48.82M USD. Revenue FY2024 65.3M USD. Operating income FY2021 −60.42M USD. Operating income FY2022 −75.48M USD. Operating income FY2023 −36.76M USD. Operating income FY2024 14.54M USD. Operating income FY2025 −17.46M USD. Net income FY2021 −41.31M USD. Net income FY2022 −54.45M USD. Net income FY2023 −31.84M USD. Net income FY2024 17.78M USD. Net income FY2025 −15.95M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—65.3M USD48.82M USD40.7M USD34.8M USD
Cost of goods sold368K USD———1.41M USD
Gross profit−368K USD65.3M USD48.82M USD40.7M USD33.39M USD
Research and development3.92M USD16.56M USD52.45M USD85.64M USD69.4M USD
Selling, general, and administrative13.53M USD23.3M USD33.13M USD30.54M USD24.41M USD
Operating expenses17.09M USD50.76M USD85.58M USD116.18M USD93.81M USD
Interest income1.03M USD3.28M USD3.35M USD284K USD510K USD
Depreciation and amortization368K USD383K USD386K USD326K USD285K USD
Operating income−17.46M USD14.54M USD−36.76M USD−75.48M USD−60.42M USD
Net income−15.95M USD17.78M USD−31.84M USD−54.45M USD−41.31M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
6 beats, 3 misses, 0 met estimates
Average EPS surprise
+70.34%
9 comparable reports
Latest EPS result
-0.66
Estimate -3.12 · Beat by 78.82%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.1-1.19-2.27-3.36Q4 '24BeatQ1 '25BeatQ2 '25No estimateQ3 '25MissQ4 '25No estimateQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 12, 2024: actual -1.2, estimate -1.7, surprise +29.41%, Beat. Q1 2025, reported Feb 12, 2025: actual -0.4, estimate -2.2, surprise +81.82%, Beat. Q2 2025, reported May 13, 2025: actual -0.39, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 29, 2025: actual -2.76, estimate -1.41, surprise -96.21%, Miss. Q4 2025, reported Nov 14, 2025: actual -0.12, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 17, 2026: actual -0.82, estimate -3.12, surprise +73.68%, Beat. Q2 2026, reported May 13, 2026: actual -0.66, estimate -3.12, surprise +78.82%, Beat. Q3 2026, reported Sep 28, 2026: actual —, estimate -3.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.84M3.91M1.97M31.88KQ1 '24EstimateQ2 '24EstimateQ3 '24EstimateQ4 '24EstimateQ1 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26Estimate
Q1 2024, reported Feb 13, 2024: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q2 2024, reported May 9, 2024: actual —, estimate 37.5K USD, surprise —, Comparison unavailable. Q3 2024, reported Sep 19, 2024: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q4 2024, reported Nov 12, 2024: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q1 2025, reported Feb 12, 2025: actual —, estimate 37.5K USD, surprise —, Comparison unavailable. Q1 2026, reported Feb 17, 2026: actual —, estimate 5.41M USD, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual —, estimate 5.41M USD, surprise —, Comparison unavailable. Q3 2026, reported Sep 28, 2026: actual —, estimate 5.41M USD, surprise —, Comparison unavailable.

LITS news

globenewswire.com

Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share

SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today…

Read source
globenewswire.com

Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

SAN DIEGO, June 19, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) ("Lite Strategy" or the "Company"), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today…

Read source
globenewswire.com

Lite Strategy Leads Strategic Investment in LitVM

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today…

Read source

LITS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LITS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
635.85K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
348.74K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
105.7K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research LITS

research.disclaimer